Sputum microbiome profiles identify severe asthma phenotypes of relative stability at 12 to 18 months
Mahmoud I. Abdel‐Aziz(GGD Amsterdam), Anke H. Maitland‐van der Zee(Utrecht University), Sven‐Erik Dahlén(Karolinska University Hospital), Susanne J. H. Vijverberg(Amsterdam University Medical Centers), Kian Fan Chung(Imperial College London), Paul Brinkman(Respiratory Clinical Trials), Ratko Djukanović(University Hospital Southampton NHS Foundation Trust), Aletta D. Kraneveld(Utrecht University), Nazanin Zounemat Kermani(IRCCS Ospedale San Raffaele), Ian M. Adcock(Imperial College London), Peter Howarth(Age UK), John Riley(GlaxoSmithKline (United Kingdom)), Stewart Bates(GlaxoSmithKline (United Kingdom)), Simone Hashimoto(Emma Kinderziekenhuis), Peter J. Sterk(Amsterdam UMC Location University of Amsterdam), Anne H. Neerincx(Amsterdam University Medical Centers)
Cited by 108
Related Papers
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
|European Respiratory Journal|2013|3.9k
An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations
|American Journal of Respiratory and Critical Care Medicine|2009|1.9k
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program
|Journal of Allergy and Clinical Immunology|2007|933
Uniform definition of asthma severity, control, and exacerbations: Document presented for the World Health Organization Consultation on Severe Asthma
|Journal of Allergy and Clinical Immunology|2010|746
Histone deacetylase 2–mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression
|The Journal of Experimental Medicine|2005|617